Immunocore Discloses Pipeline Expansion; Company Says It Is Advancing PRAME ImmTAC Including First Phase 3 Clinical Trial In Melanoma; Plans To Present Clinical Data From Phase 1/2 Clinical Trial In Melanoma, Ovarian, And Lung Cancer Throughout 2024
Benzinga Newsdesk - Jan 5, 2024, 7:12AM